An observational study in Atopic Dermatitis, sponsored by UMC Utrecht. Recruiting at 14 sites in Netherlands. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by UMC Utrecht · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Dermatitis, Atopic with a site in Netherlands — 7 open to participants now, 14 under way, 3 of them phase 3. Dermatitis, Atopic · Netherlands.
Among the 73 studies in Dermatitis, Atopic with a site in Netherlands, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 11 that started in 2018, is one of 13 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 30th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →7 of the 73 studies in Dermatitis, Atopic with a site in Netherlands are open now. Recruiting first, the newest first:
Leiden University Medical Center · Sites in Netherlands
Ages 18+ · Healthy volunteers
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 18–100
LEO Pharma · Sites in Netherlands, United States, Belgium and 10 more countries
Ages 6 mo–11 yrs
UMC Utrecht · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 28 · Phase 4 4
First in 1998; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 235 across the 59 interventional studies, 500 across the 13 observational. Of the 53 that completed or were terminated, 24 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 73 have an industry lead sponsor. The 10 most frequent:
UMC Utrecht is the lead sponsor of 364 studies on the registry; 81 are open to participants now.
UMC Utrecht has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
2 of the studies in Dermatitis, Atopic with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT03621137Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies in Dermatitis, Atopic with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.
All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study also gives Dupilumab. No intervention listed here names it: that was found by reading the record.
Assessment of effectiveness
To assess the effectiveness of new treatments in adult and pediatric patients with AD using physician measured clinical eczema scores as well as patient-reported outcome measures.
Time frame: Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)
Drug survival
To study drug survival and identify factors that affect drug survival.
Time frame: Drug survival analysis, which is the length of time a patient continues to take a particular drug, will be performed every year, with cumulative results over the years.
Side effects
To register objective and subjective side effects and to identify potential risk factors.
Time frame: Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)
Characterization of population
To characterize patient populations treated with new AD treatments in daily practice.
Time frame: Yearly from baseline up to 5 years
Characterization of side effects
To collect data from daily practice regarding side effects (incidence, severity, risk factors, treatment options, etc.).
Time frame: Yearly from baseline up to 5 years
Laboratory monitoring
To study the usefulness of laboratory monitoring during treatment in daily practice, with emphasis on subpopulations (e.g. elderly patients, patients with pre-existing liver and/or renal disease).
Time frame: Yearly from baseline up to 5 years
Long-term safety
To study the long-term safety risks including malignancies, pregnancy/paternity-related conditions, infections, and autoimmune diseases.
Time frame: Yearly from baseline up to 5 years
Comorbidities
To prospectively collect data from daily practice regarding the effect of new treatment options for AD on comorbidities (for example atopic diseases like asthma, food allergy and rhinoconjunctivitis can improve from these new drugs as many target the Th2 axis).
Time frame: Yearly from baseline up to 5 years
Dose tapering
To assess whether dose reduction of biologics can be achieved in patients with low AD activity.
Time frame: Yearly from baseline up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2018 (actual). Primary completion is estimated for Dec 2028, 131 months after the start.
Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 131 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.